|  |
| --- |
| REGISTRATION REPORT  Part B  Section 10  Assessment of the relevance of metabolites in  groundwater  Detailed summary of the risk assessment |
| Product code: ADM.00150.I.2.A  Product name: LEAXO  Chemical active substance:  Acetamiprid, 200 g/L |
| Central Zone  Zonal Rapporteur Member State: Poland |
| CORE ASSESSMENT  (Authorization acc. to Art. 33) |
| Sponsor: ADAMA Makhteshim Ltd. Applicant: Country organisation / representative of ADAMA,  as given in Part A  Submission date: August 2023  MS Finalisation date: January 2024 (initial Core Assessment)  November 2024 (final Core Assessment) |

Version history

|  |  |
| --- | --- |
| **When** | **What** |
| August 2023 | Applicant version v 1.0 |
| January 2024 | Initial zRMS assessment  The report in the dRR format has been prepared by the Applicant, therefore all comments, additional evaluations and conclusions of the zRMS are presented in grey commenting boxes. Minor changes are introduced directly in the text and highlighted in grey. Not agreed or not relevant information are ~~struck through~~ and shaded for transparency. |
| November 2024 | Final report (Core Assessment updated following the commenting period)  No additional information or assessments after the commenting period. |

Table of Contents

[10 Relevance of metabolites in groundwater 4](#_Toc97130428)

[Appendix 1 Lists of data considered in support of the evaluation 5](#_Toc97130429)

[Appendix 2 Additional information 6](#_Toc97130430)

|  |
| --- |
| Reviewer comments: This part of dossier has been submitted to support registration of the plant protection product LEAXO (product code ADM.00150.I.2.A) according art. 33 of 1107/2009.  Document refers data related to the forming of metabolites in the environment (see dRR B8). dRR Part B10 has been reviewed for the purposes of ongoing registration and also checked its compliance with the current guidelines. Information has been considered as sufficient and appropriate for concluding. |

# Relevance of metabolites in groundwater

There are no metabolites of acetamiprid that are relevant for groundwater assessment.

1. Lists of data considered in support of the evaluation

List of data submitted by the applicant and relied on

| Data point | Author(s) | Year | Title Company Report No.  Source (where different from company) GLP or GEP status Published or not | Vertebrate study  Y/N | Owner |
| --- | --- | --- | --- | --- | --- |
| - | - | - | - | - | - |

List of data submitted or referred to by the applicant and relied on, but already evaluated at EU peer review

| Data point | Author(s) | Year | Title Company Report No.  Source (where different from company) GLP or GEP status Published or not | Vertebrate study  Y/N | Owner |
| --- | --- | --- | --- | --- | --- |
| - | - | - | - | - | - |

List of data submitted by the applicant and not relied on

| Data point | Author(s) | Year | Title Company Report No.  Source (where different from company) GLP or GEP status Published or not | Vertebrate study  Y/N | Owner |
| --- | --- | --- | --- | --- | --- |
| - | - | - | - | - | - |

List of data relied on not submitted by the applicant but necessary for evaluation

| Data point | Author(s) | Year | Title Company Report No.  Source (where different from company) GLP or GEP status Published or not | Vertebrate study  Y/N | Owner |
| --- | --- | --- | --- | --- | --- |
| - | - | - | - | - | - |

1. Additional information

No further data provided.